The potential activity of EGFR/HER2 inhibitor (lapatinib) combined with HDACi Panobinostat in colon cancer cells has been demonstrated, and further evaluation of the efficacy of this combination in the treatment of CRC is warranted (LaBonte et al., 2011). This evidence concerns the gene EGFR and malignant colon neoplasm.